Adam Friend, MD
Ophthalmology · Glen Rock, NJNPI 1235109927
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,427 of the $11,675 with a category attached, or 80.7%. It is spread thinly across 20 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $45.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Bausch & Lomb Americas Inc.$2K
- Glaukos Corporation$2K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$732
- NEW World Medical,inc.$623
- plus $2K from 14 others
What the payments were for
- Travel & lodging$2,24819%
- Food & beverage$9,42781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 28 | $2,455 |
| Bausch & Lomb Americas Inc. | 32 | $2,395 |
| Glaukos Corporation | 21 | $1,974 |
| Sun Pharmaceutical Industries Inc. | 41 | $1,023 |
| AbbVie(2 entities) | 20 | $732 |
| NEW World Medical,inc. | 6 | $623 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $439 |
| Alcon | 14 | $420 |
| Harrow Eye, LLC | 22 | $333 |
| Dompe US, Inc. | 14 | $330 |
| Oyster Point Pharma, Inc. | 13 | $216 |
| Tarsus Pharmaceuticals, Inc. | 7 | $208 |
| Rxsight Inc | 2 | $158 |
| Ocular Therapeutix, Inc. | 7 | $100 |
| Thea Pharma Inc. | 4 | $69 |
| Eyevance Pharmaceuticals LLC | 3 | $61 |
| Novartis | 4 | $56 |
| Kala Pharmaceuticals, Inc. | 3 | $42 |
| Sight Sciences, Inc. | 2 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$1,683
- IC-8 Apthera IOL$1,190
- STELLARIS ELITE$1,190
- Photrexa$999
- KXL System$818
- Kahook Dual Blade$434
- Streamline Surgical System$434
- Ahmed Glaucoma Valve$434
- CEQUA$259
- XELPROS$259
- CATALYS SYSTEM$251
- RESTASIS$235
- iStent inject W$160
- Clareon$147
- Elahere$140
- BROMSITE$136
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$126
- enVista Aspire IOL$125
- LUMIGAN$125
- COMBIGAN$125
How this compares
$11,675 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $328,200 |
| RestasisCyclosporine | 160 | $179,183 |
| Cyclosporine | 66 | $41,392 |
| MieboPerfluorohexyloctane/Pf | 36 | $29,319 |
| XiidraLifitegrast | 26 | $26,562 |
| TyrvayaVarenicline Tartrate | 29 | $22,625 |
| LumiganBimatoprost | 51 | $21,705 |
| Prednisolone Acetate | 345 | $18,296 |
| CequaCyclosporine | 13 | $9,489 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 30 | $5,518 |
| Bromfenac Sodium | 22 | $4,057 |
| MoxifloxacinMoxifloxacin Hcl | 187 | $3,696 |
| ValacyclovirValacyclovir Hcl | 55 | $2,937 |
| Travoprost | 25 | $2,912 |
| Difluprednate | 17 | $2,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $330 | $328,20012 claims |
| AbbVieRestasis, Lumigan | $732 | $200,888211 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $2,395 | $55,88162 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $216 | $22,62529 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,023 | $9,48913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Glen Rock
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.